Receive up-to-the-minute news updates on the hottest topics with NewsHub. Install now.

AbbVie halts late-stage trial for lung cancer drug Rova-T

December 5, 2018 10:36 PM
32 0

(Reuters) - AbbVie Inc said on Wednesday it had halted enrollment for a late stage trial of Rova-T as a second-line therapy for advanced small-cell lung cancer, following recommendations made by an independent data monitoring committee.

The committee’s recommendations were based on shorter overall survival in the Rova-T arm, compared with the topotecan control arm, the company said.

Read more

Share in social networks:

Comments - 0